Delhi High Court Refuses Interim Relief to U.S. Drug Firm Merck & Co., Inc. (MRK)
4/5/2013 8:15:11 AM
The Delhi High Court today refused to grant interim relief on a patent row to US pharmaceuticals major Merck Sharp and Dohme (MSD) which sought a restraint on Indian firm Glenmark PharmaceuticalsBSE -0.07 % on manufacturing and marketing anti-diabetes drugs Zita and Zita-Met. Justice Rajiv Sahai Endlaw dismissed the interim application of the multinational pharma major that the Mumbai-based firm be restrained from manufacturing and selling the anti-diabetes medicines on the grounds that the salt used in the drugs were not of generic nature. MSD, in its plea, alleged that the Indian pharma company has violated its intellectual property right (IPR) over its anti-diabetes medicines, Januvia and Janumet, by coming in the market with their own drugs containing the same salts.
comments powered by